Organization (Industry)
Syntrix Biosystems (United States)
ClinicalTrials.gov lists Syntrix Biosystems (United States) as lead sponsor of 10 trials. It has 6 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Syntrix Biosystems (United States): 10 lead-sponsored trials and 1 legal-entity registration.
Disease areas (17)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 4 |
| Agnosia | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Lung Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
Showing 5 of 17 disease areas.
Trials by start year as sponsor or collaborator (12)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 1 |
| 2024 | 1 |
| 2023 | 2 |
| 2021 | 1 |
| 2020 | 3 |
| 2019 | 1 |
| 2018 | 2 |
| 2017 | 1 |
| 2014 | 1 |
Showing 10 of 12 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (6)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| LD-Aminopterin oral capsule | Psoriasis | Phase 2 | 1 |
| Decitabine | Myelodysplastic Syndromes | Phase 1 | 1 |
| PEMBROLIZUMAB | Melanoma | Phase 1 | 1 |
| SX-682 | Melanoma | Phase 1 | 1 |
| SX-682 | Myelodysplastic Syndromes | Phase 1 | 1 |
Showing 5 of 6 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Enzalutamide | 1 |
| TRAMADOL | 2 |
| Decitabine | 1 |
| PEMBROLIZUMAB | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 1 of 3 on time (n=3) |
Journals published in (2)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Journal of pharmacology and experimental therapeutics | 1 |
| The journal of pain | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 24 | 0 | 2021-05-11 |
Financing and grant events (10)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2025-06-06 | SBIR award | 903,852 | Reporter |
| 2025-04-24 | SBIR award | 627,270 | Reporter |
| 2024-09-16 | SBIR award | 400,000 | Reporter |
| 2024-06-12 | SBIR award | 745,050 | Reporter |
| 2023-07-07 | SBIR award | 400,000 | Reporter |
Showing 5 of 10 events.
Organization relationships (5)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| PRA Health Sciences | Uses vendor | 1 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Co sponsors trial with | 1 |
| M.D. Anderson Cancer Center | Co sponsors trial with | 1 |
| Lei Zheng | Co sponsors trial with | 1 |
| DF/Net Research | Co sponsors trial with | 1 |
Latest dated events (50)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-06-06 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-04-28 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-04-24 | SBIR award | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2024-11-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 50 events.
Biomarker capability evidence (80)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| AMT | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 80 evidence rows.
On Scientist.com
Syntrix Biosystems (United States) is listed as a research supplier in the Scientist.com network.
Syntrix has pioneered the development of new therapies for over 10 years. Founded in 2001, Syntrix evolved from a basic research organization to a clinical-stage company tackling some of medicine’s most high-value diseases. One thing has remained unchanged however, our shared commitment to improving the lives of patients. We have our roots in the Seattle area: home to venerable research institutions, teaching hospitals, and a thriving biotechnology community. But we also operate in every region of the globe through our collaborations with university researchers, manufacturers and clinical...
Show the full description
Syntrix has pioneered the development of new therapies for over 10 years. Founded in 2001, Syntrix evolved from a basic research organization to a clinical-stage company tackling some of medicine’s most high-value diseases. One thing has remained unchanged however, our shared commitment to improving the lives of patients.
We have our roots in the Seattle area: home to venerable research institutions, teaching hospitals, and a thriving biotechnology community. But we also operate in every region of the globe through our collaborations with university researchers, manufacturers and clinical trial teams.
- Website
- syntrixbio.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Syntrix Biosystems on Scientist.com
For prices, more details, or to contact Syntrix Biosystems, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.